CD200 and acute myeloid leukemia: Pevonedistat, a small molecule inhibitor of Nedd8-activating enzyme (neural precursor cell expressed developmentally down-regulated protein 8), which may inhibit cell proliferation and survival, in combination with 7 + 3 is being investigated in a phase 1b/2 trial in patients with AML-MRC and t-AML (NCT03330821) [48].